2/24/2026 1:00 PM Eastern
2/24/2026 2:00 PM Eastern
Bringing a life sciences company to the public markets is uniquely complex – and today’s environment raises the bar even higher.
Market volatility, evolving investor expectations, regulatory scrutiny, and the need to clearly articulate clinical, scientific, and commercial differentiation mean that management teams and boards must be exceptionally well prepared to navigate the IPO journey successfully.
This 60-minute session brings together economic forecasters and experienced life sciences specialists to provide a holistic, practical perspective on what it takes to prepare for an IPO in today’s market.
Presenters will provide an overview of current economic trends and the life sciences IPO landscape, helping participants understand the macroeconomic forces shaping valuation, timing, and investor appetite. In addition, they will explore the critical strategic, operational, financial, and governance considerations that life science companies must address well in advance of going public.
Topics include aligning scientific and clinical strategies with a compelling equity story, confirming defensible intellectual property, building a financial model that reflects scientific reality, scaling operations, and preparing boards and infrastructure for public company scrutiny. The session also will highlight common financial reporting risks that can delay or derail an IPO – and practical steps to avoid those pitfalls.
Designed for life sciences executives, finance leaders, and board members, this session will equip attendees with actionable insights to assess IPO readiness, anticipate challenges, and position their organization for long-term success as a public company.
C-suite leaders in biotech, medtech, and the life sciences ecosystem
For additional information, please contact Crowe Events.